Last reviewed · How we verify
Any platinum-based doublet chemotherapy
Platinum-based doublet chemotherapy works by interfering with DNA replication in cancer cells, ultimately leading to cell death.
Platinum-based doublet chemotherapy works by interfering with DNA replication in cancer cells, ultimately leading to cell death. Used for Non-small cell lung cancer, Small cell lung cancer, Ovarian cancer.
At a glance
| Generic name | Any platinum-based doublet chemotherapy |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Platinum-based chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Platinum-based doublet chemotherapy involves the use of two platinum-based drugs, which form platinum-DNA adducts that prevent DNA replication and transcription, ultimately leading to cell death. This mechanism is particularly effective in rapidly dividing cancer cells.
Approved indications
- Non-small cell lung cancer
- Small cell lung cancer
- Ovarian cancer
- Bladder cancer
- Head and neck cancer
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Nausea and vomiting
- Diarrhea
Key clinical trials
- Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) (PHASE2)
- Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer (PHASE2)
- Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy (PHASE3)
- A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC. (PHASE2)
- A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor (PHASE1, PHASE2)
- A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer (PHASE2)
- Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) (PHASE1)
- Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: